Regenerative Medicine Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
A bi-weekly read on Regenerative Medicine public-market moves, company news and M&A activity for September 14–28, 2026, built for operators, acquirers and advisors tracking sector-defining regulatory and transaction signals.
Key figures
- +0.9%
- Covered-set median move 7 names, close-to-close
- +0.8%
- S&P 500 benchmark same window
- +66.1%
- Surrozen (SRZN) two-week move incl. +108.4% single-day
- 10.0x
- Sector valuation lens trailing precedent median, 23 deals
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE
Executive summary
Regulatory outcomes, not transactions, carried the two-week period ending September 28, 2026: 5 of 7 covered names rose, with a median move of +0.9% against the S&P 500's +0.8%. Surrozen, Inc. (SRZN) led at +66.1% on its Investigational New Drug submission, while a federal court vacated FDA's tissue-classification determination for MiMedx Group, Inc. (MDXG)'s AXIOFILL. No new sector transactions were recorded, leaving the trailing record at 23 deals against a 10.0x valuation lens.
Key findings
- 5 of 7 covered names rose; sector median edged out the S&P 500
- Surrozen's IND submission drove the period's largest single move
- Court ruling reopens MiMedx's tissue-classification question
- No new deals printed; trailing record holds at 23 transactions
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE
Cover slide introducing the bi-weekly Regenerative Medicine industry events and M&A update for September 14–28, 2026.
This update covers what changed, who moved and why, what transacted, and what it means for Regenerative Medicine over September 14–28, 2026. We built it to give operators, acquirers and advisors a fast, evidence-based read on the two-week period.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE Pathway Rulings Move Value While the Deal Record Holds Still This update covers Regenerative Medicine movers, company news and transactions for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Regulatory Outcomes, Not Transactions, Carried the Period
Summarizes the two-week period's bottom line across the 7 covered names, close-to-close.
5 of 7 covered names finished the period higher, with a median move of +0.9% against +0.8% for the S&P 500 — so the set modestly outpaced the broader market. The largest single move came from Surrozen, Inc. (SRZN), up +66.1% including a +108.4% single-day gain, following its Investigational New Drug submission for SZN-8141. MiMedx Group, Inc. (MDXG) also stood out after a federal court vacated FDA determinations on AXIOFILL's tissue classification, reopening a question central to the sector. No new transactions were recorded, leaving the trailing record at 23 precedent deals — so this period's story is regulatory, not deal-driven.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Regulatory Outcomes, Not Transactions, Carried the Period The two-week period in one page · 7 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Most of the Covered Set Finished Higher 5 of 7 covered names rose; the median move was +0.9%, just ahead of the S&P 500 at +0.8%. 2 One Regulatory Submission Produced the Period's Largest Move Surrozen, Inc. (SRZN) gained +66.1% over the two-week period, including +108.4% on Sep 24. Shares moved following the company's Investigational New Drug submission to the FDA for SZN-8141 in diabetic macular edema. 3 A Court Ruling Puts Tissue Classification Back in Play MiMedx Group, Inc. (MDXG) announced a federal court vacated FDA determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product. Tissue pathway versus biologic licence remains the sector's central question. 4 The Transaction Record Stood Still No new sector transactions were recorded in the window. The trailing record carries 23 precedent transactions, and NeuraCap's valuation lens for the sector sits at a median of 10.0x. +66.1% Best mover — Surrozen, Inc. (SRZN) worst: AORT -8.1% · 5 up / 2 down of 7 covered +0.9% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
A Single Regulatory Step Outran the Whole Set
Ranks the individual stock price moves for the covered set against the sector median and S&P 500 benchmark.
Surrozen, Inc. (SRZN) led the covered set, gaining +66.1% for the period and +108.4% in a single session, tied to its FDA Investigational New Drug submission for SZN-8141. The sector median move was +0.9%, just ahead of the S&P 500's +0.8%, and the materiality bar for this period sat at ±5.3% on a sector-relative basis. We read each move only against filings and headlines recorded in the window — where no driver is on record, we say so. One name accounts for most of the set's dispersion, so the regulatory pathway story is doing the work here, not broad sector momentum.
Everything on this page
PUBLIC MARKET MOVERS A Single Regulatory Step Outran the Whole Set Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +0.9% · S&P 500 +0.8% · materiality bar ±5.3% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +0.9% Surrozen, Inc. (SRZN) +66.1% Shares moved following Surrozen, Inc. (SRZN) submitting an Investigational New Drug application to the FDA for SZN-8141 in diabetic macular edema, reported Sep 24, the same day the stock moved +108.4%. Pre-commercial regenerative names still reprice on regulatory steps rather than on revenue. COMPANY-SPECIFIC Organogenesis Holdings Inc. (ORGO) -8.0% No notable in-window news was identified that clearly explains the move. Organogenesis Holdings Inc. (ORGO) returned -8.0% against a median move of +0.9% across the covered set. Skin substitute sellers are read on reimbursement durability more than on any two-week move. UNEXPLAINED Artivion, Inc. (AORT) -8.1% No notable in-window news was identified that clearly explains the move. Artivion, Inc. (AORT) returned -8.1% against a median move of +0.9% across the covered set. A Core-tier implant franchise lagged a set led by the therapeutics end of the sector. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
Classification, Compliance and Surgeon Access Defined the Period's News
Details the period's highest-impact news events on tissue classification, compliance and surgeon access.
The MiMedx Group, Inc. (MDXG) court ruling vacating FDA's tissue-classification determination on AXIOFILL is the period's most consequential event, because it reopens the tissue-pathway-versus-biologic-licence question for the sector. Surrozen, Inc. (SRZN)'s Investigational New Drug submission for SZN-8141 in diabetic macular edema is the second major catalyst, and it is the one the market priced hardest. Integra LifeSciences Holdings Corporation (IART)'s surgeon-access programming rounds out the period's news. Each entry here links back to its underlying filing or article, so the read is traceable, not asserted.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS Classification, Compliance and Surgeon Access Defined the Period's News The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · GlobeNewsWire MiMedx wins federal court ruling vacating FDA classification determinations on AXIOFILL The ruling goes to whether AXIOFILL is minimally manipulated or should sit as a licensed biological product. That line sets the effective life and defensibility of a franchise in this sector. Classification outcomes can reset a market faster than a product launch does. Sep 23 · NEWS · PRNewsWire LeMaitre Vascular faces class action investigation after reported exposure of customer data The probe announced by the law firm touches compliance and data handling rather than product performance. Diligence in this sector already concentrates on compliance history, and LeMaitre Vascular, Inc. Compliance exposure is weighed alongside clinical and reimbursement position in this sector. Sep 25 · NEWS · GlobeNewsWire Integra LifeSciences brings surgeon-led liver surgery education to ACS Clinical Congress 2026 Integra LifeSciences Holdings Corporation (IART) is putting surgeon-led programming behind a long-running instrumentation line. Channel ownership and surgeon access still separate platforms from single-product sellers.
- 05M&A & STRATEGIC ACTIVITY
The Transaction Record Holds While Regulatory Outcomes Do the Work
Reviews the M&A and strategic activity record, noting no new transactions in the window against a 23-deal trailing record.
No new sector transactions printed during September 14–28, 2026, so the reference set is unchanged this period. The trailing record still carries 23 precedent transactions, and NeuraCap's valuation lens for the sector sits at a median of 10.0x. That gap between an active regulatory news cycle and a quiet deal tape is itself informative — so acquirers gain a new data point on classification risk without a new price point to underwrite against. We do not re-present prior deals as new activity here.
Everything on this page
M&A & STRATEGIC ACTIVITY The Transaction Record Holds While Regulatory Outcomes Do the Work September 14–28, 2026 · precedent transactions: 23 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record still carries 23 precedent transactions, and NeuraCap's valuation lens for the sector sits at a median of 10.0x. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 23 Recorded precedent transactions the reference set buyers and sellers price against
- 06WHAT IT MEANS
What the Period Changes for Operators, Buyers and Advisors
Translates the period's regulatory and market evidence into implications for operators, acquirers and advisors.
For owners and operators, the read is that channel and pathway execution carried the set higher, with 5 of 7 names up and a median move of +0.9%. For acquirers, the reference set gains a regulatory data point rather than a new price point, since no transactions printed and the trailing record still holds at 23 deals against a 10.0x median lens. For advisors, the evidence to lead with is the MiMedx classification ruling, Surrozen's IND submission, and Integra LifeSciences' surgeon-led programming — so classification and channel positioning are the conversations worth opening now. These are NeuraCap observations on the recorded evidence, not recommendations.
Everything on this page
WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 10.0x 8 companies in the study 3 valuation tiers Standing thesis: Regenerative Medicine Splits Across Implants, Instrumentation, Therapeutics and Adjacent Models FOR OWNERS & OPERATORS Payment Route and Channel Productivity Carried the Set Companies in the space traded higher over the two-week period, with 5 of 7 covered names rising and a median move of +0.9%. FOR ACQUIRERS The Reference Set Gains a Regulatory Data Point, Not a New Price Point No transactions printed in the window, so the reference set is unchanged and the trailing record still carries 23 precedent transactions against a 10.0x median lens. The MiMedx Group, Inc. FOR ADVISORS Lead with Classification and Channel The period's theme was regulatory pathway. The evidence to lead with is the MiMedx ruling on minimal manipulation, the Surrozen, Inc. (SRZN) Investigational New Drug submission, and Integra LifeSciences Holdings Corporation (IART) surgeon-led programming.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the sources and methodology behind the update's figures and calibrated-language conventions.
Every figure in this update links to the record it was taken from — SEC filings, press releases and established outlets, admitted in a fixed reliability order. We use calibrated language throughout, distinguishing observed moves from NeuraCap's read of their likely drivers. This page lists what the two-week period's figures rest on, so every claim in the preceding pages can be checked against its source.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Regenerative Medicine Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T183546Z_562_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · prnewswire.com
Sources and methodology
This update covers Regenerative Medicine over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 7 listed companies whose core business is Regenerative Medicine under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), Surrozen, Inc. (SRZN). 1 name below the floor was excluded from the statistics: SNWV.
Window and company universe
This update covers Regenerative Medicine over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 7 listed companies whose core business is Regenerative Medicine under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), Surrozen, Inc. (SRZN). 1 name below the floor was excluded from the statistics: SNWV.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 23 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Report · Sep 28, 2026Regenerative Medicine Sector Outlook — September 2026
- Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
- Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
- Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
Want this analysis for a company in Regenerative Medicine?
Company valuation reports run the same method against a single business — public or private.